United States Department of Veterans Affairs
Hepatitis C

Management and Treatment of Hepatitis C Viral Infection: Table 5

Home > Providers' Home > Clinical Care > Guidelines > 2006 Recommendations > Table

for Health Care Providers

Management and Treatment of Hepatitis C Viral Infection

Hepatitis C Resource Center Program
National Hepatitis C Program Office

October 2006

Table 5. Antiviral Treatments for Chronic HCV (11, 12, 60, 61)
TREATMENTRECOMMENDED DOSE
Clcr = creatinine clearance; IFN = interferon; PO = orally; SC = subcutaneous; U = units.
Combination Peginterferon Alfa Regimens with Ribavirin
Peginterferon alfa-2a (Pegasys®)180 mcg SC once weekly regardless of weight
Peginterferon alfa-2b (PEG-Intron®)1.5 mcg/kg SC once weekly up to 150 mcg/week
Ribavirin (Rebetol®, Copegus®)Genotype 1: 1,000 mg ≤75 kg OR 1,200 mg if >75 kg PO daily (in two divided doses)

Genotype 2 and 3: 800 mg PO daily (in two divided doses)
Regimens in Certain Clinical Circumstances
Peginterferon alfa-2a (Pegasys®) in hemodialysis135 mcg SC once weekly
Peginterferon alfa-2b (Peg-Intron®) in renal dysfunctionReduce dose by 25% if Clcr 30-50 mL/min

Reduce dose by 50% if Clcr 10-29 mL/min
Peginterferon alfa-2a (Pegasys®) monotherapy180 mcg SC once weekly regardless of weight
Peginterferon alfa-2b (PEG-Intron®) monotherapy1.0 mcg/kg SC once weekly up to 150 mcg/week
IFN alfa-2a (Roferon-A®)3 million U SC three times weekly
IFN alfa-2b (Intron A®)3 million U SC three times weekly
IFN alfacon-1 (Infergen®) also known as consensus IFN9 mcg SC three times weekly

15 mcg SC three times weekly in IFN nonresponders
Ribavirin dose with IFN1,000 mg PO daily if patient ≤75 kg (in two divided doses) OR

1,200 mg PO daily if patient >75 kg (in two divided doses)